Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
7.85
-0.16 (-2.00%)
Nov 4, 2024, 4:00 PM EST - Market closed
Acrivon Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for ACRV stock have an average target of 22.6, with a low estimate of 16 and a high estimate of 30. The average target predicts an increase of 187.90% from the current stock price of 7.85.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 16, 2024.
Analyst Ratings
The average analyst rating for ACRV stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $17 | Buy | Reiterates | $17 | +116.56% | Sep 16, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Hold → Strong Buy Upgrades $16 | Hold → Strong Buy | Upgrades | $16 | +103.82% | Sep 16, 2024 |
| BMO Capital | BMO Capital | Buy Reiterates $25 → $28 | Buy | Reiterates | $25 → $28 | +256.69% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +180.25% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +180.25% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
350.43K
EPS This Year
-2.48
from -2.74
EPS Next Year
-2.76
from -2.48
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 3.2M | 60.2M | ||
| Avg | n/a | 350,431 | 17.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 17,091.7% | ||
| Avg | - | - | 4,837.6% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.35 | -2.10 | -1.89 | ||
| Avg | -2.48 | -2.76 | -2.59 | ||
| Low | -2.87 | -3.44 | -3.40 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.